Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

TYRA 10.11.2024

Full Press ReleaseSEC FilingsOur TYRA Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
  • 01.10.2025 - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
  • 01.07.2025 - Eliana Merle

Recent Filings

  • 01.22.2025 - 144 Report of proposed sale of securities
  • 01.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities

-TYRA will also present two posters on PK/PD of TYRA-300 and a Trials-in-Progress from SURF301 -

CARLSBAD, Calif.,Oct. 11, 2024/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the selection of three abstracts for presentation, including a late-breaking oral presentation, at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), taking placeOctober 23-25, 2024, inBarcelona, Spain.

Details of the presentations are below:

Title: "Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)"

Session: Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug developmentDate:Friday, October 25, 2024Time: 15:36 - 15:48 hrs CESTAbstract #: LBA500

Title: "TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations"

Abstract #: 72Poster #: PB060

Title: "A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)"

Abstract #: 35Poster #: PB023

The abstracts related to the presentations are under embargo until 00.01 hrs CEST onFriday, October 25, 2024.

AboutTyra Biosciences

Tyra Biosciences, Inc.(Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based inCarlsbad, CA.

For more information about our science, pipeline and people, please visitwww.tyra.bioand engage with us onLinkedIn.

Contact:

Amy Conradaconrad@tyra.bio

(PRNewsfoto/Tyra Biosciences, Inc.)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and-anti-tumor-activity-of-tyra-300-from-surf301-at-the-36th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-ena-2024-302273982.html

SOURCETyra Biosciences

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com